New Test for Measuring Osteopontin in Breast Cancer
Author Information
Author(s): Alicia Plumer, Hongyi Duan, Sripriya Subramaniam, Lucas F Lee, Susan Miesfeldt, Ah-Kau Ng, Lucy Liaw
Primary Institution: University of Southern Maine
Hypothesis
Can a new ELISA test accurately measure osteopontin levels in patients with metastatic breast cancer?
Conclusion
The new ELISA test shows elevated osteopontin levels in metastatic breast cancer patients compared to healthy individuals.
Supporting Evidence
- The average circulating plasma osteopontin level in healthy volunteers was 1.2 ng/ml.
- Patients with metastatic breast cancer had an average osteopontin level of 4.76 ng/ml.
- The new ELISA showed high sensitivity and accuracy in measuring osteopontin levels.
Takeaway
Researchers created a new test to measure a protein called osteopontin in blood, which can help doctors understand breast cancer better.
Methodology
The study developed and characterized five monoclonal antibodies against osteopontin and created an ELISA to measure its levels in blood samples.
Potential Biases
Potential bias due to differences in assay formats and standards used for comparison.
Limitations
The variability in existing ELISA tests for osteopontin may complicate accurate quantification.
Participant Demographics
55 healthy volunteers and 40 women with metastatic breast cancer.
Statistical Information
P-Value
0.0042
Statistical Significance
p = 0.0042
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website